Skip to content

Glossary · Valuation

Accretion / dilution analysis

Does this deal raise or lower the acquirer's earnings per share? It is the first question a listed buyer's board asks, and it says almost nothing about whether the deal creates value.

Valuation
Category
16 November 2026
Updated

In one sentence

Does this deal raise or lower the acquirer's earnings per share? It is the first question a listed buyer's board asks, and it says almost nothing about whether the deal creates value.

What it is

Accretion/dilution asks a single question about an acquisition: what does it do to the buyer’s earnings per share?

Combine the earnings. Subtract the financing cost of any debt used, and the earnings foregone on any cash spent. Add expected synergies. Divide by the share count after any new shares are issued. Compare with what the acquirer would have earned on its own.

Why it is mostly arithmetic

This is the part that gets lost. Whether a deal is accretive is largely determined by two things that have nothing to do with the quality of the acquisition.

The multiple relationship. In a stock deal, if the acquirer trades on a higher price-earnings multiple than it is paying for the target, the deal is accretive. If lower, dilutive. That is a mechanical consequence of exchanging expensive shares for cheaper earnings.

The financing cost. In a cash deal, if the target’s earnings yield, earnings divided by price, exceeds the after-tax cost of the debt raised to buy it, the deal is accretive.

The reverse also holds: a company paying a full multiple for a business that will transform it can be dilutive for two or three years and still be the best decision its board ever took.

What it is genuinely useful for

Two things, both narrower than the attention it receives.

  1. Understanding how a deal will be reported. Listed acquirers are judged on EPS. A dilutive deal needs explaining, and management teams structure around that: more cash, less stock, or synergies front-loaded in the guidance.
  2. Reading the acquirer’s assumptions. The synergy number required to make a deal accretive is often disclosed, and it is a test of plausibility. When Kimberly-Clark announced its acquisition of Kenvue it pointed to approximately $2.1bn of expected run-rate synergies, net of reinvestment, and said the deal would be accretive to adjusted EPS by year two.1 Numbers of that size are a commitment, and they are the first thing shareholders measure management against afterwards.

Why a private seller should care

It looks like a listed-company concern, and mostly it is. But it shapes the offer you receive:

  • It drives the mix. A buyer worried about dilution will push for more stock and less cash, or for deferred consideration, which changes how much of your price is certain. See enterprise value vs equity value.
  • It explains the synergy questions. A listed buyer needs a synergy case to defend the price. That is why diligence probes cost overlap so hard.
  • It sets a ceiling of a different kind. Where a financial buyer’s limit comes out of an LBO model, a listed strategic buyer’s limit is often the price at which the deal stops being defensible to its own shareholders.

Common mistakes

  1. Reading accretion as value creation. It is a function of multiples and financing.
  2. Ignoring the synergy assumption. Accretion that depends on synergies is a forecast, not a result.
  3. Comparing EPS impact across differently financed deals. Cash and stock deals are not comparable on this measure.
  4. Forgetting the share count. Issuing stock to pay for earnings is the whole mechanism; the denominator does as much work as the numerator.

Sources

  1. Kimberly-Clark, “Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader”, press release filed as Exhibit 99.1 to its Form 8-K (3 November 2025). ↩

Frequently asked questions

What is accretion dilution analysis?

A calculation of what a transaction does to the acquirer's earnings per share. Combine the two companies' earnings, adjust for financing costs and synergies, divide by the enlarged share count, and compare with what the acquirer would have earned alone. Higher is accretive, lower is dilutive.

Why does accretion matter to acquirers?

Because listed company management is measured on earnings per share, and a dilutive deal is harder to explain to shareholders and to the market. It is a reporting and communication concern more than an economic one, which is why it carries more weight in boardrooms than its analytical content justifies.

Does accretive mean the deal is good?

No. Whether a deal is accretive depends mostly on the relationship between the two companies' earnings multiples and how the deal is financed. A company on a high multiple buying one on a low multiple with cash will usually be accretive even if the acquisition is strategically poor, and a genuinely good acquisition can be dilutive for years.

What is the rule of thumb?

Paying with stock is accretive when the acquirer's price-earnings multiple is higher than the multiple being paid for the target, and dilutive when it is lower. Paying with cash is accretive when the target's earnings yield exceeds the after-tax cost of the debt used to fund it. Both are arithmetic, not judgement.